Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lipocine

3.35
+0.05001.52%
Post-market: 3.450.1000+2.99%19:27 EDT
Volume:13.32K
Turnover:44.74K
Market Cap:17.92M
PE:-4.38
High:3.42
Open:3.36
Low:3.22
Close:3.30
Loading ...

Company Profile

Company Name:
Lipocine
Exchange:
NASDAQ
Establishment Date:
1997
Employees:
17
Office Location:
675 Arapeen Drive,Suite 202,Salt Lake City,Utah,United States
Zip Code:
84108
Fax:
801 994 7388
Introduction:
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Directors

Name
Position
Mahesh V. Patel
President, Chief Executive Officer and Chairman of the Board
Jeffrey A. Fink
Independent Director
Richard Dana Ono
Independent Director
Stephen A. Hill
Lead Independent Director
John W. Higuchi
Director

Shareholders

Name
Position
Mahesh V. Patel
President, Chief Executive Officer and Chairman of the Board
Morgan R. Brown
Executive Vice President and Chief Financial Officer
Nachiappan Chidambaram
Vice President, Product Development